CN104189886A - 一种用于分娩的复方药物组合物及其应用 - Google Patents
一种用于分娩的复方药物组合物及其应用 Download PDFInfo
- Publication number
- CN104189886A CN104189886A CN201410487013.6A CN201410487013A CN104189886A CN 104189886 A CN104189886 A CN 104189886A CN 201410487013 A CN201410487013 A CN 201410487013A CN 104189886 A CN104189886 A CN 104189886A
- Authority
- CN
- China
- Prior art keywords
- oxytocin
- injection
- birth
- giving
- medicament composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 100
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title abstract description 15
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims abstract description 168
- 101800000989 Oxytocin Proteins 0.000 claims abstract description 167
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims abstract description 167
- 229960001723 oxytocin Drugs 0.000 claims abstract description 167
- UNBRKDKAWYKMIV-QWQRMKEZSA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 UNBRKDKAWYKMIV-QWQRMKEZSA-N 0.000 claims abstract description 72
- 229960000328 methylergometrine Drugs 0.000 claims abstract description 20
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims abstract description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims abstract 9
- 239000007924 injection Substances 0.000 claims description 49
- 238000002347 injection Methods 0.000 claims description 49
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 14
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 13
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 11
- 239000011976 maleic acid Substances 0.000 claims description 11
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- -1 and wherein Chemical compound 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 210000000754 myometrium Anatomy 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003169 placental effect Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 230000032696 parturition Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 208000037805 labour Diseases 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 102400000050 Oxytocin Human genes 0.000 description 158
- 241000209140 Triticum Species 0.000 description 47
- 235000021307 Triticum Nutrition 0.000 description 47
- NOFOWWRHEPHDCY-DAUURJMHSA-N Methylergonovine Maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 NOFOWWRHEPHDCY-DAUURJMHSA-N 0.000 description 39
- 229940045385 methylergonovine maleate Drugs 0.000 description 39
- CEDGTLOSFDBJKR-KVXRPJDVSA-N (6ar,9r)-n-[(2s)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide;(2s)-1-[(4r,7s,10s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,1 Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1.C([C@H]1C(=O)NC(C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 CEDGTLOSFDBJKR-KVXRPJDVSA-N 0.000 description 32
- 108010075578 syntometrine Proteins 0.000 description 31
- 210000004291 uterus Anatomy 0.000 description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 20
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 16
- 229960001405 ergometrine Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 230000001954 sterilising effect Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000008602 contraction Effects 0.000 description 13
- 239000003708 ampul Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 238000010253 intravenous injection Methods 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 10
- 230000009471 action Effects 0.000 description 8
- 210000002376 aorta thoracic Anatomy 0.000 description 8
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000006906 Vascular Ring Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 229950002007 estradiol benzoate Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004279 Oxytocin receptors Human genes 0.000 description 2
- 108090000876 Oxytocin receptors Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001595 contractor effect Effects 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229960003133 ergot alkaloid Drugs 0.000 description 2
- 229940069585 ergot preparation Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 108010021522 pork drug combination 30:70 pork; isophane insulin insulin Proteins 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 208000010238 Uterine Inertia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YREISLCRUMOYAY-IIPCNOPRSA-N ergometrine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 YREISLCRUMOYAY-IIPCNOPRSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410487013.6A CN104189886B (zh) | 2014-09-22 | 2014-09-22 | 一种用于分娩的复方药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410487013.6A CN104189886B (zh) | 2014-09-22 | 2014-09-22 | 一种用于分娩的复方药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104189886A true CN104189886A (zh) | 2014-12-10 |
CN104189886B CN104189886B (zh) | 2017-03-15 |
Family
ID=52075356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410487013.6A Active CN104189886B (zh) | 2014-09-22 | 2014-09-22 | 一种用于分娩的复方药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104189886B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105125481A (zh) * | 2015-08-19 | 2015-12-09 | 河北智同医药控股集团有限公司 | 一种马来酸甲麦角新碱注射液及其制备方法 |
CN114712483A (zh) * | 2022-05-12 | 2022-07-08 | 成都倍特药业股份有限公司 | 一种麦角新碱缩宫素复方注射液及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580057A (zh) * | 2012-03-14 | 2012-07-18 | 南京先宇科技有限公司 | 含有麦角新碱与缩宫素类似物的药物组合物及制备方法 |
-
2014
- 2014-09-22 CN CN201410487013.6A patent/CN104189886B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580057A (zh) * | 2012-03-14 | 2012-07-18 | 南京先宇科技有限公司 | 含有麦角新碱与缩宫素类似物的药物组合物及制备方法 |
Non-Patent Citations (3)
Title |
---|
SINGH NISHA: "Methylergometrine and carboprost tromethamine prophylaxis for", 《J OBSTET GYNECOL INDIA》 * |
WORLD HEALTH ORGANIZATION: "Ergometrine maleate", 《THE WHO ESSENTIAL MEDICINES LIBRARY》 * |
高金玲: "产后出血的药物缩宫素与麦角新碱疗效评价", 《中外医疗》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105125481A (zh) * | 2015-08-19 | 2015-12-09 | 河北智同医药控股集团有限公司 | 一种马来酸甲麦角新碱注射液及其制备方法 |
CN105125481B (zh) * | 2015-08-19 | 2019-01-29 | 河北智同医药控股集团有限公司 | 一种马来酸甲麦角新碱注射液及其制备方法 |
CN114712483A (zh) * | 2022-05-12 | 2022-07-08 | 成都倍特药业股份有限公司 | 一种麦角新碱缩宫素复方注射液及其制备方法和用途 |
CN114712483B (zh) * | 2022-05-12 | 2023-09-29 | 成都倍特药业股份有限公司 | 一种麦角新碱缩宫素复方注射液及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104189886B (zh) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Serrano et al. | Intramuscular administration of diphenylhydantoin: histologic follow-up studies | |
CN102144965A (zh) | 一种更加稳定的醋酸卡贝缩宫素注射剂 | |
CN104189886B (zh) | 一种用于分娩的复方药物组合物及其应用 | |
WO2018113272A1 (zh) | 一种含缩宫素类似物的药物组合物及其制备方法和用途 | |
CN102144980B (zh) | 一种更加稳定的lhrh拮抗剂冻干粉针剂 | |
CN107343902A (zh) | 一种具有缓解甲状腺功能减退功效的中草药组合物及其制备方法与应用 | |
CN107198677A (zh) | 黄体酮混悬型长效注射剂及其制备方法和黄体酮混悬注射粉针 | |
CN113855689B (zh) | 黄杞苷或其异构体在制备治疗子宫内膜异位症的药物中的用途 | |
CN102145162B (zh) | 一种治疗早产药物的注射剂 | |
CN113350358B (zh) | 远志皂苷元单用或联合羟基红花黄色素a在制备改善缺血性脑卒中后认知损害药物中的应用 | |
CN104324250A (zh) | 一种缺血性脑卒中用中药组合物及其制备方法 | |
Caldeyro-Barcia | Oxytocin in pregnancy and labour | |
CN112656792B (zh) | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 | |
CN102139010A (zh) | 一种治疗流产后阴道出血的中药 | |
CN114042150B (zh) | 一种口服干细胞因子复合物及其用途 | |
CN102988399A (zh) | 一种药物组合物及用途和制剂 | |
CN103127106B (zh) | 盐酸苯环壬酯治疗或缓解心肌缺血再灌注所诱发的心肌损伤的用途及含有其的药物组合物 | |
RU2759168C1 (ru) | Способ активации функции яичников при сниженном овариальном резерве | |
CN107951885B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
CN112353933B (zh) | 一种预防和/或治疗子宫肌瘤的药物及其制备方法 | |
CN106668865B (zh) | 用于治疗脑缺血的药物组合物、制剂及其应用 | |
CN102166187B (zh) | 重组人血管内皮抑制素缓释注射油制剂及其制备工艺 | |
Fahim et al. | The role of placental 5-hydroxytryptamine in the pathogenesis of toxemia of pregnancy | |
CN113855714A (zh) | 一种预防脑卒中的灵芝子实体萃取物及其制备方法和应用 | |
CN107281208B (zh) | 一种预防和治疗脑卒中的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Huo Liru Inventor after: Li Zhan Inventor after: Zhao Qing Inventor after: Yang Jiannan Inventor after: Liu Erjun Inventor after: Zhou Jing Inventor after: Zhang Hui Inventor before: Huo Liru Inventor before: Yu Jian Inventor before: Yang Jiannan Inventor before: Liu Erjun Inventor before: Zhou Jing |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HUO LIRU YU JIAN YANG JIANNAN LIU ERJUN ZHOU JING TO: HUO LIRU LI ZHAN ZHAO QING YANG JIANNAN LIU ERJUN ZHOU JING ZHANG HUI |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 210009 Gulou District, Jiangsu, Nanjing Ma Street, building 26, No. 5 Patentee after: NANJING GRITPHARMA CO.,LTD. Address before: 210009 Gulou District, Jiangsu, Nanjing Ma Street, building 26, No. 5 Patentee before: NANJING JIQUN PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Longmian road Jiangning District of Nanjing City, Jiangsu province 211112 No. 568 No. 9 Building 5 layer Patentee after: NANJING GRITPHARMA CO.,LTD. Address before: 210009 Gulou District, Jiangsu, Nanjing Ma Street, building 26, No. 5 Patentee before: NANJING GRITPHARMA CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211222 Address after: 430040 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Life Science (Wuhan) Co.,Ltd. Address before: 211112 5th floor, building 9, 568 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Patentee before: NANJING GRITPHARMA CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430000 No.1 Xiaoxiang West Road, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Medical Nutrition Science (Wuhan) Co.,Ltd. Country or region after: China Address before: 430040 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee before: Yuanda Life Science (Wuhan) Co.,Ltd. Country or region before: China |